All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
ICML 2019 | RG6146 and venetoclax in DLBCL
During ICML 2019, the Lymphoma Hub were pleased to speak to Michael Dickinson, Peter MacCallum Cancer Center, Melbourne, AU, about a study investigating the combination of RG6146, venetoclax and rituximab in...
ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL
Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox